New hope for Tough-to-Treat colon cancer? trial tests combo attack
NCT ID NCT04362839
Summary
This early-stage trial tested a new three-drug combination for people with advanced colorectal cancer that had spread and stopped responding to standard chemotherapy. The main goal was to find the safest dose of the drug regorafenib when given with two immunotherapy drugs (nivolumab and ipilimumab). Researchers hoped the combination would help the immune system fight the cancer and slow or shrink tumors in 39 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.